Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus
Kyverna Therapeutics reduced its workforce by approximately 16% during Q1 2025 as part of a company-wide effort to streamline operations and focus resources on late-stage drug development and commercialization objectives.12345
The company had 119 full-time employees as of March 31, 2025, according to SEC filings. The reduction is expected to extend its financial runway into 2027, with $242.6 million in cash reported at the end of the quarter.15
This restructuring comes as Kyverna advances KYV-101, its lead investigational CD19 CAR T cell therapy, into pivotal late-stage trials for stiff person syndrome (SPS) and prepares a Phase 3 trial for myasthenia gravis.15
Q1 2025 financial results showed R&D expenses of $37.4 million and a net loss of $44.6 million.15
The 16% staff cut was one of the largest biopharma layoffs in Q1 2025, reflecting broader industry trends of cost containment and operational refocus.3
Sources:
1. https://www.stocktitan.net/news/KYTX/kyverna-therapeutics-provides-business-update-and-reports-first-4a6fropko8zv.html
2. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025
3. https://www.biospace.com/job-trends/the-5-largest-biopharma-layoffs-of-q1-2025
4. https://www.threads.com/@whatlayoff/post/DJplzO3K2fH/-layoff-alert-california-kyverna-therapeutics-has-laid-off-16-of-its-workforce-d